Forbes-Tate

Forbes-Tate filed a Q3 report for Amgen USA, Inc. on October 18, 2026, reporting $50,000 in lobbying income.

Lobbying for Amgen USA, Inc. · Biotech company that discovers, develops, manufactures and delivers human theraputics

As filed: FORBES-TATE for AMGEN USA, INC.

All filings by Forbes-Tate · Everything Amgen USA, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 18, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Lobbyists on this filing 1

MICHAEL ALEXANDER WILLIAMS New on this filing

Previously held: Legislative Director, Rep. Lucy McBath (2021-2022); Legislative Assistant, Rep. Lucy McBath (2019-2020); Legislative Aide, Sen. Doug Jones (2019); Legislative Correspondent, Sen. Doug Jones (2018-2019)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Taxation/Internal Revenue Code

Issues related to the implementation of international tax and tax reform in the Tax Cuts and Jobs Act (PL 115-97); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Medicare/Medicaid

Issues related to prescription drug pricing; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Medical/Disease Research/Clinical Labs

Issues related to Biosimilars; Issues related to drug pricing; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Budget/Appropriations

Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to the Medicaid Drug Rebate Program; Issues related to the 340b program.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.